Bayer Aktiengesellschaft (FRA:BAYN)

Germany flag Germany · Delayed Price · Currency is EUR
28.06
+0.13 (0.48%)
At close: Aug 29, 2025
0.48%
Market Cap27.57B
Revenue (ttm)46.17B
Net Income (ttm)-3.42B
Shares Outn/a
EPS (ttm)-3.48
PE Ration/a
Forward PE5.95
Dividend0.11 (0.39%)
Ex-Dividend DateApr 28, 2025
Volume2,744,824
Average Volume2,720,861
Open27.94
Previous Close27.93
Day's Range27.62 - 28.36
52-Week Range18.38 - 31.03
Betan/a
RSI54.55
Earnings DateAug 6, 2025

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]

Industry Chemicals and Allied Products
Founded 1863
Employees 91,864
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BAYN
Full Company Profile

Financial Performance

In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.

Financial Statements

News

Bayer's E.L.Y. Wins “AI-based AgTech Solution of the Year” In 2025 AgTech Breakthrough Awards Program

Annual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe Annual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe

9 days ago - GlobeNewsWire

Bayer settles Sky Valley cases over chemical PCB

Bayer said on Monday its Monsanto unit reached agreements in principle with more than 200 plaintiffs to resolve the so-called Sky Valley Education Center product liability cases related to the chemica...

12 days ago - Reuters

Bayer Aspirin Introduces Aspirina to the U.S. Pain Market

Bayer’s Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic co...

15 days ago - Wallstreet:Online

Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market

WHIPPANY, N.J.--(BUSINESS WIRE)-- #consumerhealth--Bayer's Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispan...

15 days ago - Business Wire

LumenHaus Powers Bayer 04 Leverkusen as Official Premium Partner for 2025/26 Season

LEVERKUSEN, Germany, Aug. 15, 2025 (GLOBE NEWSWIRE) -- LumenHaus, Germany's forefront innovator in smart home energy solutions, has officially signed as an Official Premium Partner of Bayer 04 Leverku...

15 days ago - GlobeNewsWire

Why are Indoco Remedies shares up 2% today? Explained

Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Ab...

17 days ago - Business Upturn

Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology

BERLIN & SAN DIEGO--(BUSINESS WIRE)--Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclus...

18 days ago - Business Wire

Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal

German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.

18 days ago - Reuters

Bayer, Kumquat Biosciences Team Up on New Potential Cancer Drug

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will take the drug to market.

18 days ago - WSJ

Bayer says it has cut 12,000 jobs so far under restructuring push

Bayer said on Wednesday it had cut about 12,000 full-time positions since the start of a restructuring programme to speed up decision-making and reduce managerial and administrative positions.

24 days ago - Reuters

Here's why the Bayer share price may rebound after earnings

Bayer share price pulled back to €27.6 on Tuesday as investors waited for its financial results. It has dropped by 7.3% from its highest level this year, and is about 50% above its lowest level this y...

25 days ago - Invezz

Bayer gains after raising 2025 outlook

4 weeks ago - Seeking Alpha

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

4 weeks ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

4 weeks ago - CNBC Television

Bayer Ups Guidance After Pharmaceuticals Unit Outperforms

4 weeks ago - The Wall Street Journal

Bayer increases Roundup litigation provisions by $1.37 billion

German pharmaceutical company Bayer said on Thursday it had set aside an additional 1.2 billion euros ($1.37 billion) in provisions to address ongoing Roundup litigation in the United States.

4 weeks ago - Reuters

Bayer Boosts 2025 Forecast, Sets US Legal Provisions

Bayer's Pharmaceuticals division has exceeded expectations, prompting an optimistic revision of its 2025 financial outlook, with anticipated sales of up to 48 billion euros and a strong EBITDA forecas...

4 weeks ago - Wallstreet:Online